- Conditions
- Pmm2-CDG, CDG1A
- Interventions
- Placebo, Acetazolamide
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Rochester, Minnesota • Philadelphia, Pennsylvania • Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pmm2-CDG, Phosphomannomutase 2 Deficiency
- Interventions
- GLM101
- Drug
- Lead sponsor
- Glycomine, Inc.
- Industry
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Rochester, Minnesota
- Conditions
- Phosphomannomutase 2 Deficiency
- Interventions
- Not listed
- Lead sponsor
- Glycomine, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 3
- States / cities
- Rochester, Minnesota • Philadelphia, Pennsylvania • Seattle, Washington
- Conditions
- Pmm2-CDG, Phosphomannomutase 2 Deficiency, Phosphomannomutase 2 Congenital Disorder of Glycosylation, Phosphomannomutase II Congenital Disorder of Glycosylation, Phosphomannomutase II Deficiency
- Interventions
- Epalrestat, Placebo
- Drug
- Lead sponsor
- Maggie's Pearl, LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Phosphomannomutase 2 Deficiency, PMM2-CDG
- Interventions
- GLM101 (Part A, Double-blind), Placebo (Part A, Double-blind), GLM101 (Part B, Open-label)
- Drug
- Lead sponsor
- Glycomine, Inc.
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Minneapolis, Minnesota • New York, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- Pmm2-CDG, Phosphomannomutase 2 Deficiency
- Interventions
- GLM101
- Drug
- Lead sponsor
- Glycomine, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 4
- States / cities
- Minneapolis, Minnesota • New York, New York • Philadelphia, Pennsylvania + 1 more